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Introduction
The use of cholinesterase inhibitors (ChEIs) for the
treatment of Alzheimer’s disease (AD) began in Canada
in 1997, representing a signiﬁcant advance in treat-
ment at that time. Three ChEIs are currently approved
in Canada for the symptomatic treatment of AD: done-
pezil (Aricept
 ; Pﬁzer, New York, NY), rivastigmine
(Exelon*, Novartis, Basel, Switzerland) and galanta-
mine (Reminyl
 ; Janssen Ortho, Titusville, NJ). While
all increase the level of acetylcholine (ACh) in the
brain, they differ substantially in mechanism of action,
inhibitory potency, brain selectivity and metabolism.
Rivastigmine is the only approved ChEI that
targets both acetylcholinesterase (AChE) and butyryl-
cholinesterase (BuChE). Importantly, the patho-
physiological changes associated with AD are
associated with an increased ratio of BuChE-to-AChE
expression in the limbic system and cortex (2–4).
Alzheimer’s disease is characterised by a progres-
sive cholinergic denervation in speciﬁc regions of the
forebrain, particularly the hippocampus and neocor-
tex (5). As cognitive dysfunction ensues, the loss of
ACh-producing neurons in major brain areas also
leads to an impaired ability to perform activities of
daily living (ADL), problems with attention (lack
of concentration/distractibility) and the emergence of
mood and behavioural symptoms (6).
Most of the earlier trials of pharmacotherapies for
AD focused primarily on the domain of cognition
(i.e. memory loss). However, one of the most
important early beneﬁts of ChEIs is on the subcogni-
tive domain of attention. Patients with AD are often
described by caregivers as being unable to concen-
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SUMMARY
The objective of this study was to investigate the impact of rivastigmine therapy
on attention, apathy, anxiety and agitation in patients with mild-to-moderate Alz-
heimer’s disease (AD) in a real-world clinical setting. Patients with mild-to-moder-
ate AD were enrolled in the study by physicians across Canada. They were treated
with open-label rivastigmine (dose at the discretion of the prescribing physicians)
for a period of 6 months. Changes from baseline in attention, apathy, anxiety and
agitation were assessed using an abbreviated Clinician’s Global Impression of
Change at 3- and 6-month visits. The Mini Mental State Examination (MMSE) was
also used at these visits. Use and changes in use of psychotropic medications were
recorded, as were changes in caregiver burden. Analyses of subgroups (outpatients
vs. institutionalised patients) were also performed. A total of 2119 patients were
enrolled in the study by 375 physicians. At baseline, 91% had deﬁcits in attention,
85.4% had symptoms of anxiety, 78.5% exhibited apathy and 70.1% showed agi-
tation. At 6 months, 67.5% of evaluable patients had improved on the symptom
of attention, while 62.3%, 62.6% and 56.0% had improvements in anxiety,
apathy and agitation respectively. The percentages with improvements were higher
in the institutional subgroup than among outpatients. There was an overall mean
improvement of 1.1 points on the MMSE at 6 months. Approximately four times
as many caregivers reported a reduced burden than an increased burden at
6 months (40.3% vs. 10.3%). The majority of patients treated with rivastigmine
experienced improvements in attention, anxiety, apathy and agitation. These real-
life ﬁndings further demonstrate the proven efﬁcacy of rivastigmine in patients with
mild-to-moderate AD.
What’s known
• In placebo-controlled clinical trials in Alzheimer’s
disease, rivastigmine has been shown to be
effective in improving cognition, neuropsychiatric
symptoms, activities of daily living and global
function.
• Attention, anxiety, apathy and agitation are
known to be common symptoms in Alzheimer’s
disease.
• In placebo-controlled clinical trials, caregiver
burden has been reduced by administering
cholinesterase inhibitors.
What’s new
• This article assesses the prevalence of attention
deﬁcits, anxiety, apathy and agitation in a non-
selected, real-world cohort of AD patients treated
in the community.
• It evaluates rivastigmine therapy in this real-
world, non-standardised clinical setting.
• It shows how clinicians can use simple tools (i.e.
the modiﬁed Clinical Global Impression of
Change scale) to assess and monitor their
patients in routine practice.
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that were previously easily performed. It is thought
that deﬁcits in attention may underlie the difﬁculties
with everyday activities in the early stages of AD (7).
In addition, mood and behavioural symptoms
(e.g. apathy, anxiety and agitation) are very common
in AD, affecting up to 80% of a typical clinical pop-
ulation (8,9). Mood and behavioural symptoms are
prevalent in the early stages of AD and their occur-
rence may precede a diagnosis by up to 3 years (9).
Once present, these symptoms tend to worsen,
becoming more prominent and recurrent manifesta-
tions of the disease (10).
The most frequently reported mood and beha-
vioural symptoms are apathy (exhibited by 70% of
patients), agitation (occurring in 60% of patients)
and anxiety (48% of patients); irritability, dysphoria,
aberrant motor behaviour, disinhibition, delusions
and hallucinations are also common manifestations
(9).
In the presence of these symptoms, normal func-
tioning deteriorates and quality of life is reduced,
both for the patient and the caregiver (11). As sever-
ity increases, these symptoms can add to caregiver
distress and often lead to institutionalisation of the
patient (12).
Thus, the effective treatment of mood and beha-
vioural symptoms in AD has the important potential
to reduce the personal, social and economic burden
of dementia. Indeed, the importance of treating AD-
related mood and behavioural symptoms is under-
scored by recommendations that measures of
improvement in mood and behaviour be included in
all new clinical trials for AD (13,14). Some AD spe-
cialists have begun to consider ChEIs in the manage-
ment of AD-related attention and mood and
behavioural disturbances.
Study rationale
Emerging clinical data suggest that, in addition to
their cognitive beneﬁts, ChEIs may improve or delay
such symptoms as attention deﬁcits or mood and
behavioural disturbances of AD. Medications with
regional speciﬁcity for brain areas most affected in
AD might have the potential to provide a more
effective treatment for AD-related mood and beha-
vioural symptoms (15). Rivastigmine has demonstra-
ted broad beneﬁts across cognitive and functional
domains of AD (16–19). Data also indicate that
treatment with rivastigmine as early as possible in
the disease process is likely to offer the best chance
of maintaining long-term function (20). Most
importantly, preliminary information from several
open-label studies, including EXTEND (21), have
demonstrated that the effect of rivastigmine on
mood and behaviour might be more signiﬁcant than
previously surmised and, perhaps, even more clinic-
ally meaningful than the beneﬁt on cognition. Riv-
astigmine may improve and/or delay the symptoms
of mood and behaviour (17,22,23), particularly with
respect to the symptoms of apathy, anxiety and agi-
tation, while reducing and/or delaying the use of
concomitant psychotropic medications (24,25).
Study objectives
The primary objective of the EXACT (Exelon*
Therapy to ACT on the four As of AD) study was to
evaluate the efﬁcacy of rivastigmine in the manage-
ment of the symptoms of attention, apathy, anxiety
and agitation (the ‘four As of AD’) in patients with
AD in a real-world clinical setting. A secondary
objective was to evaluate the use of concomitant
psychotropic medications during treatment with
rivastigmine.
Study population
For inclusion into the study, patients had to meet
the following inclusion criteria: clinical diagnosis of
mild-to-moderate AD (MMSE ‡ 10 and £ 26) and
for which rivastigmine treatment is deemed appro-
priate according to the treating physician; living in
the community or institutionalised; having a regular
informant/caregiver (at least three contacts per week)
and able to give written, informed consent (or hav-
ing a legal representative who can give written,
informed consent).
Patients who met any of the following criteria
were excluded from participation: patients with a
known hypersensitivity to rivastigmine or its compo-
nents; patients with a medical condition that repre-
sents a contraindication to rivastigmine; female
patients of child-bearing potential; patients who have
been initiated on a psychotropic medication within
the last 2 months and patients taking an investiga-
tional drug or participating in another study.
Methodology
EXACT was a naturalistic, multi-centre, observational
study, the methodology of which was designed by an
independent Steering Committee of AD specialists.
Before the start of the study, the protocol, patient
informed consent and any other appropriate docu-
ments were submitted to an independent ethics com-
mittee and all ethical requirements were met.
Physicians enrolled in the study received an intro-
ductory letter by mail to explain the objectives and
format of the study. They were then subject to a
Study Site Initiation, intended to update participa-
ting physicians on applicable good clinical practice
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conduct of the study to the investigator and all
appropriate site personnel, and to provide an oppor-
tunity for the staff to collectively resolve any ques-
tions or problems related to the study.
As this was an observational study, the decision to
initiate ChEI therapy with rivastigmine was made as
per normal medical practice prior to the patient’s
participation in the study. This study sought only to
collect information on patients meeting the appro-
priate entry criteria.
Intervention
All patients in the EXACT study were enrolled on
the basis of having been prescribed rivastigmine
recently. To ensure that patients were using rivastig-
mine appropriately, physicians were asked to instruct
their patients on appropriate dosing. The following
recommendations were provided as a guide only, as
individual tolerance to increases in dose may vary:
a. Start at rivastigmine 1.5 mg b.i.d. (with breakfast
and dinner) for 4 weeks.
b. Increase to therapeutic dose of 3 mg b.i.d. (with
breakfast and dinner).
For many patients, no further dose increase may
be required. However, dose increases above 3 mg
b.i.d. could be considered following a complete eval-
uation of the patient’s condition. Some patients may
derive additional beneﬁts by further increasing the
dose of rivastigmine to 4.5 mg b.i.d. after a mini-
mum of 4 weeks on the previous dose. If even
greater efﬁcacy is required, a ﬁnal dose increase to
6 mg b.i.d. was possible. It was recommended
according to the study protocol that this increase
should be carried out only after a minimum of
4 weeks on the previous dose.
Each patient was enrolled in the EXACT study for
a period of 6 months. The patient (or his/her medi-
cation insurance plan, if applicable) was responsible
for the cost of rivastigmine.
Variables assessed
The primary efﬁcacy variables used in this study were
the abbreviated Clinical Global Impression of Change
scale (CGI-C) and the Mini Mental State Examina-
tion (MMSE, performed according to provincial
requirements). The abbreviated CGI-C scale was used
to assess the symptoms of attention, apathy, anxiety
and agitation. The following subdomains of the CGI-
C were used to assess the severity of the patient’s
symptoms within each domain:
• Attention ¼ concentration / distractibility
• Apathy ¼ indifference / diminished initiative / lesser
involvement in usual activity
• Anxiety ¼ worrying / ruminations / nervousness
• Agitation ¼ restlessness / pacing / unwarranted req-
uests/repetitive sentences
At baseline, clinicians were asked to rate each
patient as normal or mildly, moderately or severely
impaired for each of the four symptoms. At 3 and
6 months, physicians rated their impression of
change as improved (markedly, moderately or min-
imally), worsened (markedly, moderately or minim-
ally) or unchanged.
Caregiver burden was assessed; caregivers were
asked to rate the burden of caring for the patient as
‘not present’, ‘mild’, ‘moderate’ or ‘severe’ at baseline
and at months 3 and 6.
The pattern of use of psychotropic medications
(antipsychotics, anxiolytics, antidepressants, hypnot-
ics and mood stabilisers) was also tracked at baseline,
3 and 6 months.
Safety and tolerability were assessed by recording
adverse events and serious adverse events.
Study physicians were required to report any seri-
ous adverse event occurring in a patient after provi-
ding informed consent and until 4 weeks after the
patient ended participation in the study.
While study physicians were asked to record all
adverse events, with such a large number of trial
investigators (n ¼ 375, mostly primary-care clini-
cians) the steering committee decided that for this
type of naturalistic study, the inter-investigator vari-
ability in adverse event reporting would be vast,
reducing the chances of obtaining valid adverse event
information.
Furthermore, rivastigmine is an agent with a long-
track record of clinical use and a signiﬁcant body of
safety evidence from placebo-controlled clinical trials.
The objective of this study was to evaluate the efﬁc-
acy of the drug in a real-life, naturalistic manner. As
such, the steering committee decided not to attempt
to assess and report overall safety and tolerability in
this cohort.
Data collection and follow-up
The prescribing physician collected information from
the patient at registration and at two additional vis-
its: (1) a 3-month postregistration consultation and
(2) a 6-month postregistration consultation.
Apart from the two study-required visits, physi-
cians were asked not to deviate from their regular
medical practice, scheduling patient visits as deemed
necessary. The patient’s medical care was at the
entire discretion of the physician.
Patients were free to withdraw from the EXACT
study at any time or could be withdrawn by their
physician for any reason. Physicians were asked to
note the reasons for withdrawal on the Case Report
Form.
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The results are presented based on the intention-to-
treat approach. Analysis of the efﬁcacy end-points
consisted of summary statistics for observed cases.
Imputation methods were not used for missing data.
The CGI-C and MMSE were analysed and summa-
rised using descriptive statistical methods. In all cases
where they were collected, the average MMSE scores
were summarised using mean and standard deviation
values between registration and the ﬁnal study visit.
For all patients enrolled in the study, the CGI-C
scores obtained at visits 2 and 3 were described with
respect to the baseline symptom evaluation using a
frequency distribution (frequencies and proportions).
For visit 1, the use of psychotropic concomitant
medications (drug class, name and dose) was
assessed using a frequency distribution. For both
subsequent visits, changes in the intent to use these
concomitant medications (same dose; higher dose,
lower dose; discontinuation; use of new medication)
were assessed using frequencies and proportions.
Results
Baseline demographics
A total of 2119 patients were enrolled in the study
by 375 physicians across Canada. Of these, 1652
(78.1%) were outpatients, 433 (20.4%) were living in
institutional settings and 34 (1.6%) were registered
as unknown. Baseline demographics are summarised
in Table 1. The mean age of the participants was
81.7 years, women made up 60.1% of the cohort and
the mean duration of AD since diagnosis was
2.1 years.
For three-quarters of patients in the study
(74.4%), rivastigmine was the ﬁrst ChE inhibitor
prescribed. One-ﬁfth of patients (366 patients, 20%)
had previously been treated with donepezil, 71
patients (3.9%) with galantamine and 20 patients
(1.1%) with both donepezil and galantamine.
Participant attrition
Of the 2119 patients enrolled, 2115 (99.8%) received
a baseline evaluation; 1612 (76.1%) had valid case
report forms at 3 months and 1166 (55.0%) were
evaluable at 6 months (Figure 1). The majority of
the missing information was due to the fact that
evaluations were not returned by the study physi-
cians for many of their patients. At 3 months, for
example, evaluations were not received for 506
patients. At the 6-month visit, evaluations were not
received for 955 patients. Whether these patients had
dropped out or their physicians simply had not sub-
mitted the records is unknown.
In addition to unreturned records, many study
physicians returned incomplete evaluations. At the
baseline visit, there were 210 incomplete evaluations;
at 3 months, 108 of the 1612 evaluations were
incomplete and at 6 months, 349 of 1166 were
incomplete. Incomplete records were used in the
analyses when the relevant data were present.
Because of this, the total number of patients evalu-
ated varies from end-point to end-point within these
results.
The proportion of evaluable outpatients to inpa-
tients remained relatively constant throughout the
study, with a small and gradual shift towards a larger
proportion of inpatients. At baseline, the proportion
Table 1 Baseline demographics by enrolment criteria (all patients enrolled)
Characteristic Overall Outpatient Institutionalised Unknown
Age (years)
n 2087 1632 431 24
Mean 81.7 80.8 84.9 83.5
SD 8.15 8.1 7.55 6.77
Range 30–105 36–104 30–105 72–102
Gender
n 2119 1652 433 34
Men (%) 821 (38.7) 690 (41.8) 123 (28.4) 8 (23.5)
Women (%) 1273 (60.1) 953 (57.7) 306 (70.7) 14 (41.2)
Unknown (%) 25 (1.2) 9 (0.5) 4 (0.9) 12 (35.3)
Duration of AD (years)
n 1832 1423 388 21
Mean 2.1 2.0 3.2 2.1
SD 2.01 1.81 2.41 1.44
Range 0–25 0–25 0–16 0.5–6
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3, it was 76.6/23.1.
The proportion of evaluable drug-naive patients
vs. those switched from other ChEIs (approximately
3 : 1) remained constant throughout the study.
There were 99 patient records available at visit 3
with documented reasons for withdrawal of study
medication. Nausea was the most common adverse
effect cited as a reason for withdrawal (24 of 99
withdrawals, 24.2%).
Rivastigmine dose
Of the 1166 patients at 6 months, there were a total
of 1063 patients (91.2%) still using rivastigmine,
with 99 no longer using the drug and four for
whom the answer was not provided. The 3.0 mg
b.i.d. regimen was the most common at 6 months
(642 patients, 60.4% of patients), while 156 (14.7%)
ﬁnished the study on the 4.5 mg b.i.d. regimen and
44 (4.1%) completed the study taking rivastigmine
6.0 mg b.i.d.
MMSE results
Of a possible total score of 30, the overall average
MMSE score at baseline was 20.8 (±4.7 standard
deviation). Not surprisingly, the mean baseline
MMSE score was considerably higher for the outpa-
tient group (21.4 ± 4.4) than for the institutionalised
group (18.8 ± 5.2).
At 6 months, both groups had improved from
baseline, with the mean score increasing in the out-
patient group to a total mean score of 22.5 (±5.0)
and in the institutionalised group to 19.7 (±5.0). The
overall mean MMSE score increased from 20.8 to
21.9 (±5.1) (Figure 2).
Severity at baseline
At the initial visit, there was a high prevalence of the
four symptoms under investigation. Attention deﬁcits
were present in 91% (1916/2106) of patients. Of the
total population, 81.4% had mild-moderate attention
Patients enrolled:
n = 2,119
No evaluations received (visit 1):
n = 4
Visit 1: Baseline (0 month)
Visit 2: 3 months
Visit 3: 6 months
Complete evaluations: 1,894
Ineligible: 11
Evaluations w/ missing info: 210
No evaluations received (visit 2):
n = 506
Complete evaluations: 1,492
Ineligible: 12
Evaluations w/ missing info: 108
No evaluations received (visit 3):
n = 955
Patients with evaluation submitted (visit 3):
n = 1,166
Patients with evaluation submitted (visit 2):
n = 1,612
Patients with evaluation submitted (visit 1):
n = 2,115
Complete evaluations: 808
Ineligible: 9
Evaluations w/ missing info: 349
Figure 1 Participant ﬂow
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Figure 2 Mean (±SD) changes in Mini Mental State
Examination (MMSE) from baseline (observed cases)
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no deﬁcit.
More than 85% of patients demonstrated anxiety
at baseline (73.7% mild-moderate, 11.7% severe),
while almost 80% demonstrated apathy (68% mild-
moderate, 10.5% severe) and more than 70% showed
signs of agitation (59.5% mild-moderate, 10.6%
severe) (Figure 3).
The coexistence of symptoms was very common
(Table 2). At baseline, the number of patients with
all four of anxiety, apathy, agitation and attention
deﬁcits was 1143 (54.0%). A further 517 (24.5%)
had three of the four and 312 (14.8%) had two of
the four symptoms. There were 103 patients (4.9%)
with only one of the four symptoms and 33 patients
(1.6%) with none.
The prevalence of these symptoms was also
recorded based on site of care. A total of 93.5% of
institutionalised patients had attention difﬁculties,
including 18.7% of the total cohort whose difﬁculties
were assessed as severe. Among institutionalised
patients, 92.4% had anxiety, with 18.5% classiﬁed as
severe; 87.8% of institutionalised patients demonstra-
ted apathy, including 16.4% with severe symptoms.
Finally, 84.5% of patients demonstrated agitation,
including 19.9% in whom this was judged to be severe.
The prevalence of each symptom (broken down
by total and severe) is shown in Figure 4(A,B) for
outpatients and institutionalised patients respectively.
CGI-C results
Overall, in each of the four symptoms, the majority
of patients for whom records were submitted
improved on rivastigmine therapy at 6 months, while
some patients remained unchanged and only a small
percentage was deemed to have worsened. In the
symptom of attention, 67.5% of evaluable patients
improved, while 24.8% remained unchanged and
7.7% worsened. The corresponding ﬁgures for anxi-
ety were 62.3%, 30.9% and 6.8%; for apathy 62.6%,
30.0% and 7.4% and for agitation 56.0%, 37.2% and
6.8% respectively (Figure 5).
9.0
81.4
9.5
Attention
n = 2,106
21.6
68.0
10.5
Apathy
n = 2,107
14.6
73.7
11.7
Anxiety
n = 2,108
29.8
59.5
10.6
Agitation
n = 2,108
Severe
Mild-moderate
Normal
Figure 3 Baseline prevalence (%) and severity of attention difﬁculties, anxiety, apathy and agitation (observed cases)
Table 2 Number and percentage of patients with
anxiety, agitation, apathy and attention difﬁculties at
baseline
Number of symptoms n (%)
0 symptoms 33 (1.6)
1 symptom 103 (4.9)
2 symptoms 312 (14.8)
3 symptoms 517 (24.5)
4 symptoms 1143 (54.2)
Total 2108 (100)
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of attention, anxiety, apathy and agitation, 76.0%,
71.4%, 74.4% and 69.8% of patients with available
records showed improvement, while only 7.2%, 5.7%,
5.7% and 5.0% worsened respectively (Figure 6).
Caregiver burden
At baseline, most caregivers (92.1%) indicated that
they considered caregiving a burden: 37.6% rated the
burden as mild, 44.1% rated it as moderate and
10.4% rated it as severe. At visit 2, 3 months into
rivastigmine therapy, more than three times as many
caregivers considered the burden to have lessened
than those who considered it to be increased (34.7%
vs. 10.6%). At the study’s conclusion at 6 months,
approximately four times as many caregivers repor-
ted a reduced burden than an increased burden
(40.3% vs. 10.3%) (Figure 7).
Use of psychotropic medication
At baseline, there were 491 patients who reported
taking antidepressants (23.2% of the total cohort),
400 antipsychotics (18.9%), 302 anxiolytics (14.3%),
143 hypnotics (6.8%) and 34 mood stabilisers
(1.6%). At 6 months, of the 1166 evaluable patients,
236 had been taking an antidepressant at baseline
93.5 92.4
87.8
84.5
18.7 18.5 16.4
19.9
0
20
40
60
80
100
Attention Anxiety Apathy Agitation
%
 
o
f
 
p
a
t
i
e
n
t
s
Total Severe
90.3
83.7
76.0
66.4
7.3 9.9 9 8.3
0
20
40
60
80
100
(A)
(B)
Attention
(n = 1,650)
Anxiety
(n = 1,652)
Apathy
(n = 1,651)
Agitation
(n = 1,652)
%
 
o
f
 
p
a
t
i
e
n
t
s
Total Severe
Figure 4 (A) Prevalence and severity of attention
difﬁculties, anxiety, apathy and agitation among outpatients
at 6 months (observed cases). (B) Prevalence and severity
of attention difﬁculties, anxiety, apathy and agitation
among institutionalised patients at 6 months (observed
cases, n ¼ 433)
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Figure 5 Proportion of patients experiencing improvement,
no change or worsening of attention difﬁculties, anxiety,
apathy and agitation at 6 months (observed cases)
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Figure 6 Proportion of patients experiencing improvement,
no change or worsening of attention difﬁculties, anxiety,
apathy and agitation at 6 months (observed cases,
institutionalised cohort, n ¼ 262)
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Figure 7 Proportion of caregivers reporting improvement,
no change or worsening of caregiver burden at 6 months
(observed cases)
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iolytic (12.0%), 58 a hypnotic (5.0%) and 16 (1.4%)
a mood stabiliser.
Of these patients, most did not have a change in
their regimen. More patients either had their dose
lowered or discontinued – than had their doses
increased (Figure 8). For those patients taking anxio-
lytics at baseline, for example, 107 of the 140 patients
(76.4%) did not have a change in their regimens,
while 33 (23.6%) had either a reduction in dose or a
discontinuation. It should be noted that there were
also a number of patients who were not taking
psychotropic medication at baseline who subse-
quently received such treatment during the study.
The numbers of patients with new prescriptions for
each of the studied classes were antidepressants, 29;
antipsychotics, 36; anxiolytics, 12; hypnotics, 10 and
mood stabilisers, 2.
Discussion
The primary results of this study show that most AD
patients, regardless of whether they are treated in the
community or in an institution, can beneﬁt from
ChEI therapy with rivastigmine.
These ‘real-life’ results add to the clinical trial evi-
dence base with this agent in AD, which includes
several earlier-phase, placebo-controlled, randomised
trials showing a beneﬁcial effect of rivastigmine treat-
ment (16–18,26).
The emergence and worsening of multiple mood
and behavioural symptoms contributes signiﬁcantly
to the high cost, both direct and indirect, associated
with the treatment of AD (an estimated $5.5 billion
annually in 2000) (27). Effective treatment with
ChEIs may help to reduce this burden.
The symptoms investigated in this study – atten-
tion, anxiety, apathy and agitation – were chosen
because of their high prevalence rates and need for
treatment. Problems in these areas often arise early
in the course of disease and can persist and worsen
over time. While historical data have shown that
there is signiﬁcant overlap in these symptoms [a
1996 study reported concurrent symptom presenta-
tion in as many as 20% of patients (10)], the present
study found that the prevalence of concurrent symp-
toms was much higher. The proportion of patients
with at least two symptoms was 93.5%, including
54.0% who presented with all four. One explanation
for this difference is the deﬁnition of the presence of
symptoms. There can be considerable inter-rater
variability in the assessment of symptoms in the
absence of a set list of criteria. In the current study,
the physicians were provided with deﬁnitions for the
presence or absence of the four symptoms and it was
found that rivastigmine therapy was associated with
improvements in agitation and attention in the
majority of patients. The number of patients deriving
beneﬁt from therapy far outweighed those that did
not. Only 6.8% (agitation and anxiety) to 7.7%
(attention) of patients had worsening of these symp-
toms during the trial.
While agitation, anxiety and apathy are all troub-
ling symptoms, difﬁculties with attention may be
particularly problematic in AD, as this can impact
many different aspects of daily living. While mem-
ory deﬁcits often receive the most scrutiny, non-
memory attention-related functions (e.g. ability to
concentrate) are also important for carrying out
daily tasks. In the current study, more than 90% of
patients had attention difﬁculties at baseline. After
6 months of rivastigmine therapy, most patients
either improved (67.5%) or remained the same
(24.8%) in this symptom.
Prior evidence shows that rivastigmine may be
particularly robust in ADL. In the 2-year EXCEED
study, published in 2005 (19), rivastigmine demon-
strated statistically signiﬁcant superiority in efﬁcacy
over donepezil on the AD Cooperative Study Acti-
vities of Daily Living (ADCS-ADL) scale. Studies
in dementia with Lewy Bodies and in Parkinson’s
Disease dementia, where deﬁcits in focused and
sustained attention are larger than in AD, have
also shown that rivastigmine is associated with sig-
niﬁcant improvements in measures of attention
(28,29).
Rivastigmine is a dual inhibitor of both AChE and
BuChE (30), both of which are responsible for the
hydrolysis of ACh. While AChE is the predominant
enzyme in healthy brains, in patients with AD, the
activity of AChE declines over the course of disease,
while the activity of BuChE increases (2–4). Research
has also shown that BuChE is particularly concentra-
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which are key areas for the regulation of neuropsy-
chiatric symptoms (31).
The fact that many more patients improved than
deteriorated on rivastigmine among the institutional-
ised patients (who typically have more advanced dis-
ease) may be interpreted as support for the
hypothesis that BuChE inhibition becomes more
important as the disease progresses.
In the present study, the most notable change in
psychotropic medication was for anxiolytics; 33 of
140 (23.6%) patients taking anxiolytics at baseline
either had their doses reduced or discontinued
during the trial. No patients required a dose increase.
This ﬁnding, coupled with the favourable effects of
rivastigmine on the symptom of anxiety (62.3% of
patients improved vs. 6.8% worsened), suggests that
rivastigmine has a considerable anxiolytic effect of its
own.
Study limitations
This study is especially valuable in that it reﬂects the
Canadian experience of how physicians are managing
their patients in everyday practice. The open-label
design, however, may be associated with physician
and/or caregiver bias because of an inherent desire
for the patient to improve – a fault common to all
open-label studies. This bias may apply to any of the
study’s outcomes – the abbreviated CGI-C, the
MMSE, the caregiver burden and psychotropic drug
use – as investigators were aware that each of these
was a study outcome.
Moreover, the high drop-out rates, as a result of
follow-up compliance, may add bias. High drop-out
rates are a common occurrence in open-label studies.
In a 2003 open-label evaluation of ChE inhibitor
treatment in AD, for example, 73 of 173 patients
(42.2%) were evaluable at 1 year (32).
However, evaluation of baseline characteristics of
drop-outs showed that they were comparable to the
group continuing on in the study. Hence a positive
study outcome is not likely due to a higher dropout
rate among more severe patients.
In addition, it should be noted that rates of
decline in symptoms are heterogeneous among AD
patients; comparing outcome data with baseline data
may, therefore, be misleading.
Inherent in this type of study is the tendency to
have a large percentage of incomplete or missing
patient records for the follow-up visits. However,
when the reader is aware of the design limitations of
a real-life study, he or she is able to interpret the
ﬁndings accordingly. The limitations inherent in
community-based studies do not marginalise the
importance of the information collected from the
observed cases.
Conclusions
The results of the EXACT study reinforce the obser-
vation that attention, anxiety, apathy and agitation
are all very common symptoms even in mild-
to-moderate AD. The majority of patients treated
with rivastigmine experienced improvements in each
of these four symptoms; this was true for both com-
munity-dwelling and institutionalised patients. These
real life ﬁndings further demonstrate the proven
efﬁcacy of rivastigmine in patients with mild-
to-moderate AD.
The improvements in anxiety, apathy, agitation
and attention were also accompanied by improve-
ments in caregiver burden, a highly desirable out-
come in AD management.
The effectiveness of rivastigmine in achieving these
results may be partly attributable to its mechanism
of action, which is unique among ChEIs. Inhibition
of BuChE may help explain rivastigmine’s beneﬁt,
particularly in those patients with more advanced
disease.
The link between improvements in attention
seen in this study and improvements in ADL
documented elsewhere with rivastigmine is hypo-
thetical and provocative. Testing this hypothesis in
a randomised, controlled fashion would be a
welcome addition to the evidence base in AD
management.
These ﬁndings, from a naturalistic, community-
based study using simple clinical evaluation tools
(i.e. the modiﬁed CGI-C) need not be interpreted in
isolation as being conclusive proof of rivastigmine’s
efﬁcacy. Previous placebo-controlled clinical trials
have amply demonstrated the efﬁcacy of this agent.
However, these results support the use of such sim-
ple clinical evaluation tools as a means to identify
and monitor common AD symptoms.
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